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Amyloidosis is the generic name for conditions characterized by the tissue deposition of 
protein fibrils having a  E-pleated  sheet conformation.  In man,  at least three major 
varieties of amyloid fibril  proteins have been  identified:  amyloid of immunoglobulin 
origin,  amyloid of neurohormonal origin,  and the nonimmunoglobulin  amyloid of un- 
known origin which consists of protein AA. Immunoglobulin amyloid occurs in patients 
with myeloma-associated  amyloidosis,  and in some primary amyloid syndromes; neu- 
roendocrine amyloid is usually localized to tissues of neuroectodermal  origin where the 
major fibril protein is a  hormone or prohormone;  and amyloid protein  AA occurs in 
patients with amyloidosis secondary to chronic inflammatory  diseases, such as rheuma- 
toid arthritis, familial Mediteranean fever, and leprosy. Immunoglobulin  and neuroendo- 
crine amyloid have not been described in the mouse. To date, all murine amyloid proteins 
studied are similar (1) and show amino acid sequence homology with AA proteins from 
man, monkey, mink, guinea pig, and duck (2). 
Antisera to denatured AA fibrils cross-react with a serum protein designated SAA, 
which is thought to be a precursor of  the AA fibril protein, as its NHs-terminal sequence 
is identical to that of  AA (3, 4). Murine SAA is similar in structure to human SAA in that 
it has a native mol wt of 160,000 and it can be dissociated to a more stable species of mol 
wt 12,500 (5-7). Recent studies suggest that human SAA is an acute-phase  protein (8), 
which is elevated in a variety of acute and chronic conditions (9). Elevated SAA levels 
have been detected by double immunodiffusion, within 24 h of endotexin administration 
in mink and mice (10). 
In this study we utilize a solid-phase radioimmunoassay for AA protein (6) to 
characterize the acute-phase nature of murine SAA in response to bacterial 
lipopolysaccharide (LPS) and casein, which are known to induce amyloidosis in 
mice when given by repeated daily injections. Several studies have suggested 
that  immune  dysfunction is  important  in  amyloidogenesis and  in  order  to 
evaluate this,  a  comparison was made of the ability of LPS, a  known B-cell 
mitogen, to stimulate SAA elevation in 12 strains of  mice. These included T-cell- 
deficient nude mice, two strains (C3H/HeJ and CBAJN) known to be defective in 
a range of  B-cell activities, including stimulation by LPS, as well as strains that 
have been commonly used for amyloid induction in the past. The SAA response 
of  two syngeneic strains, C3H/HeN and C3H/HeJ, has been compared using LPS 
extracted in phenol from Salmonella typhosa  or Escherichia  coli K235.  The 
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amyloid resistance of AJ mice and colchicine-treated  mice has been assessed to 
examine whether this  resistance is  a  result  of decreased acute-phase SAA 
production. Finally, preliminary studies on the site of origin of SAA are re- 
ported. 
Materials and Methods 
Animals.  6- to 8-wk-old male mice were obtained from either The Jackson Laboratory, Bar 
Harbor, Maine or from Animal Production, National Institutes of Health, Bethesda, Md. Strains 
tested were Swiss Webster GP, C57BL6, C57BL6Be,  CDF, DBA/2FD, CBA/N, CBA/J, BALB/c, 
nu/nu(BALB), AJ, C3H/HeN, and C3H/HeJ. 
SAA Inducers.  LPS extracted by the Westphal method (W) from S. typhosa (Difco Laborato- 
ries, Detroit, Mich.) was given at the sublethal dose  of 50  ~g intraperitoneally (i.p.).  Phenol- 
extracted LPS from E. coli K235 was kindly donated by Doctors J. Ryan and L. M. Glode, NIH. 
Casein Hammersten and azocasein were injected in saline i.p.  at a dose of 14 mg in 0.2 ml. 
Colchicine.  Colchicine was given 1-4 h before injection of LPS at a dosage of up to 0.1 mg i.p., 
which had previously been shown to prevent the formation of amyloidosis in mice (11, 12). 
Tissue Origin ofSAA.  Mice were sacrificed at the height of an acute SAA response to LPS and 
homogenates of lung, heart, thymus, lymph node,  spleen, kidney, and liver were incubated with 
10% (vol/vol) formic acid for 24 h at 37°C, before being assayed by radioimmunoassay for AA crose- 
reacting material. In order to minimize the amount of SAA-rich blood remaining in the organs, 
anesthetized animals were exchange transfused with saline before death, using about four times 
total blood volume by cardiac perfusion. All organs except spleen looked pale after this procedure. 
Radioimmunoassay for SAA.  A solid-phase radioimmunoassay for murine AA was developed 
using the method recently described for the human  AA protein  (1,  6).  Rabbit anti-mouse AA 
(kindly made available by Dr. Scott Pollock, NIH) was purified by affinity chromatography (6, 13). 
Serum samples  were  incubated  at  37°C for  24  h  in  10%  formic acid before  assay  on  plastic 
microtitration plates coated with anti-AA immunoglobulin. 
Results 
Strain Differences.  An initial screening experiment of SAA response to LPS 
S. typhosa  in 12 strains of mice showed marked strain variation (Fig.  1). The 
SAA concentration for all strains except C3H/HeJ was elevated by 8 h and rose 
from a baseline of less than 200 ng/ml to more than 200 ~g/ml by 24 h. At this 
stage a precise comparison cannot be made among the other 11 strains, except to 
note that the thymus-deficient  nude mice had high baseline SAA levels, which 
increased aider LPS administration, and no abnormality in the response of CBA/ 
N mice was noted. 
The Acute-Phase SAA Response.  A more detailed time-response experiment 
in C3H/HeN mice (Fig. 2a) showed a dramatic increase in SAA levels, begin- 
ning 4-6 h after LPS and rising to a maximum at 18-22 h. Control animals given 
saline showed no rise in SAA. In contrast to C3H/HeN in which amyloid is easily 
induced, AJ mice are amyloid resistant (14). However, their time-SAA response 
curves are very similar (Figs.  2a and 2 b ). Casein and azocasein administration 
also caused elevation in SAA levels to 150/~g/ml by 8 h  in C3H/HeN and AJ 
mice.  C3H/HeJ mice produced similar increases in SAA concentration aider 
casein, in contrast to their diminished SAA response to LPS. 
Tissues harvested at the height of the SAA response to LPS showed that liver 
homogenates had 20 times and kidney homogenates 10 times the concentration 
per gram wet weight of tissue of AA cross-reacting material found in organs 
from a  control animal,  which had received saline.  Spleen,  lung,  and heart 
homogenates had low SAA concentrations in beth control and test animals. McADAM  AND  SIPE  BRIEF  DEFINITIVE  REPORT  1123 
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FIG.  1.  SAA response of 12 strains of mice to i.p. 50/~g S. typhosa (W). Two mice of each 
species were bled from the orbital sinus at time points 0, 8 h, and 24 h after LPS. Control 
mice of each strain bled at 24 h  aider saline showed no rise in SAA level. 
Experiments with colchicine were designed to assess whether its documented 
activity of preventing amyloid induction in mice (11, 12) could be attributed to 
blocking the acute elevations of SAA observed aider LPS or casein injections. 
However, pretreatment of mice with colchicine, in dosages which block amyloid 
induction, did not cause any decrease in SAA levels observed at 8 and 24 h, and 
colchicine alone caused no rise in SAA levels. 
Dose-Response in C3H/HeJ Mice.  The low SAA response of C3H/HeJ mice 
to  LPS  administration was  investigated by comparison with  the  syngeneic 
strain C3H/HeN using two different phenol-extracted LPS preparations from S. 
typhosa and E. coli K235 (Fig.  3).  C3H/HeJ animals were less sensitive than 
C3H/HeN mice to both LPS preparations, in terms of lethality and their SAA 
response. A maximal SAA concentration of 750/~g/ml was obtained with 5/~g of 
either LPS preparation in C3H/HeN mice; the LDso was 100/~g with S. typhosa 
LPS and between 100-250  /~g with E.  coli  K235 LPS.  But in  the C3H/HeJ 
animals 1,000 /~g LPS S. typhosa and more than 3,000/~g of the E. coli K235 
material were required to stimulate levels of  SAA comparable to that induced in 
C3H/HeN  mice and none of the  animals died at  those  dosages.  Individual 
variability was particularly noted in C3H/HeN animals. 
Discussion 
For over 100  yr,  secondary amyloidosis has largely remained an  abstruse 
interest of pathologists as an untreatable, progressive condition which compli- 
cates chronic, longstanding infectious, or inflammatory diseases. It therefore 1124 
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FIG.  2.  (a) SAA response of C3H/HeN and (b) amyloid-resistant AJ mice after i.p. 50/~g 
LPS S. typhosa (W); (O--S), test; (O--O), control animals (i.p. saline). 
comes as a surprise to find that the precursor protein of the amyloid AA fibril is 
a normal serum protein which fluctuates many hundred-fold within hours of an 
acute stimulus.  A  report that SAA acts as an immunosuppressant  in in vitro 
assays  (15)  indicates  the  possible functional  significance  of this  acute-phase 
protein. 
In  this  study two polyclonal B-lymphocyte mitogens,  LPS and  casein  (16), 
have been shown to cause acute elevation of SAA concentration in 12 strains of 
mice. These included the T-cell-deficient nude mice and the CBA/N strain which 
are thought to have immature B cells. However, C3H/HeJ animals,  which are 
insensitive to many of the actions of LPS (17),  produced low levels of SAA in 
response to two preparations  of LPS (S. typhosa and E. coli K235). The SAA 
response  at  high  LPS  dosages  might  be  explained  by contamination  of the 
phenol-extracted LPS with a  cell wall peptide mitogen (18). 
In contrast to the low SAA response of C3H/HeJ mice to LPS, they resembled 
C3H/HeN in SAA response to casein derivatives which, like LPS, are thought to 
be B-cell mitogens. This finding supports the concept that the defect in C3H/HeJ 
is limited to a range of B-cell responses to LPS. Mice treated with colchicine and McADAM  AND  SIPE  BRIEF  DEFINITIVE  REPORT  1125 
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FIG.  3.  LPS dose-SAA  response curves of C3H/HeN and C3H/HeJ animals after two typos 
of LPS: S. typhosa  (W)  and E.  coli  K235  (phenol extracted).  Clinical manifestations of 
diarrhea and conjunctivitis were noted at dosages of  LPS over 5/~g in C3H/HeN mice (LD~, 
100-250/~g) but were not seen in C3H/HeJ mice, none of which died after LPS. 
AJ mice have been shown to be  resistant to  amyloid induction.  Since they 
produce normal quantities  of SAA in  response to  LPS,  it  appears that  the 
amyloid resistance is  related,  not to  SAA synthesis or release, but to  the 
processing and catabolism of SAA at the lysosomal level, where fibril formation 
is thought to occur. 
Although the SAA concentration is highest at 24 h, when liver, and to a lesser 
extent, kidney were the organs containing most AA cross-reactivity, amyloid 
fibrils are not observed in tissues until 7-10 days later. Interaction with antibod- 
ies and overloading of the lysosemal enzyme systems which normally process 
SAA may be reasons why amyloid deposition does not occur immediately and 
requires prolonged antigenic stimulation. 
Summary 
The serum precursor SAA of the secondary amyloid protein AA has been 
detected by solid-phase radioimmunoassay as a normal serum a-globulin of mol 
wt 160,000, which dissociates to a more stable 12,500 dalton moiety on treatment 
with formic acid.  In 12  strains of mice, including T-cell-deficient nude mice, 
treated with the amyloid-inducing agents lipopolysaccharide (LPS) or casein, 
SAA behaved as an acute-phase reactant. SAA concentration rose to about 750 
/~g/ml by 24 h  and returned to less than 1 /~g/ml by 48 h. Since the amyloid- 
resistant colchicine-treated mice and AJ mice had a normal SAA response to 
LPS, it appears that their resistance to amyloid induction is due to the nature of 
their SAA processing rather than decreased SAA production. C3H/HeJ mice, 
which have defective B-lymphocyte responses to LPS, required extremely high 
dosages of LPS to cause SAA elevation, although their SAA response to casein 
was normal. This suggests that SAA is an acute-phase protein produced as a 1126  McADAM  AND  SIPE  BRIEF  DEFINITIVE  REPORT 
result of B-lymphocyte stimulation.  Preliminary evidence suggests that at the 
height  of an  acute  SAA response,  liver homogenates  are  particularly  rich  in 
protein AA cross-reacting material. 
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